Tg Therapeutics (TGTX) Cash from Investing Activities (2011 - 2026)

Tg Therapeutics' Cash from Investing Activities history runs 16 years deep, the most recent figure standing at -$9.9 million for Q1 2026.

• On a quarterly basis, Cash from Investing Activities rose 23.74% year-over-year to -$9.9 million in Q1 2026; TTM through Mar 2026 was $16.9 million, a 457.77% increase from a year earlier, with the FY2025 full-year figure at $13.8 million, up 1431.95% from the prior year.
• Cash from Investing Activities rose to -$9.9 million in Q1 2026 per TGTX's latest filing, from -$15.6 million in the prior quarter.
• Across five years, Cash from Investing Activities topped out at $46.4 million in Q3 2025 and bottomed at -$44.8 million in Q4 2023.
• The 5-year median for Cash from Investing Activities is -$6.2 million (2023), against an average of -$4.0 million.
• Across the five-year window, Cash from Investing Activities slumped 8396.3% in 2022 and jumped 596.71% in 2025, its largest moves.
• Year by year, Cash from Investing Activities stood at $16.3 million in 2022, then plunged by 375.09% to -$44.8 million in 2023, then jumped by 135.28% to $15.8 million in 2024, then sank by 199.05% to -$15.6 million in 2025, then surged by 36.92% to -$9.9 million in 2026.
• Per Business Quant, the three latest TGTX Cash from Investing Activities figures stand at -$9.9 million (Q1 2026), -$15.6 million (Q4 2025), and $46.4 million (Q3 2025).